Axovant Sciences Gets a Buy Rating from Jefferies

By Jason Carr

In a report released yesterday, Biren Amin from Jefferies reiterated a Buy rating on Axovant Sciences (NYSE: AXON), with a price target of $31. The company’s shares opened today at $21.93.

According to, Amin is a 4-star analyst with an average return of 3.9% and a 48.4% success rate. Amin covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Stemline Therapeutics Inc, and Lion Biotechnologies Inc.

Axovant Sciences has an analyst consensus of Strong Buy, with a price target consensus of $27.

Based on Axovant Sciences’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $0 and GAAP net loss of $47.81 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $29.67 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. It offers RVT-101 product which is an orally administered therapy that improves cognition and daily functioning of dementia patients. The company was founded on October 31, 2014 and is headquartered in London, the United Kingdom.